Combining Exercise, Protein Supplementation and Electric Stimulation to Mitigate Muscle Wasting and Improve Outcomes for Survivors of Critical Illness - the ExPrES Study
Abstract Background: The combination of neuromuscular electrical stimulation (NMES) with high protein supplementation (HPRO) to preserve muscle mass and function has not been assessed in ICU patients. We compared the effects of a multimodal intervention combining NMES and HPRO with mobility and strength rehabilitation program (NMES+HPRO+PT) to standardized ICU care (SC). Methods: Over 14 days the SC group received usual critical care and rehabilitation while the NMES+HPRO+PT received 30 minutes NMES twice daily for 10 days applied to the quadriceps and dorsiflexors bilaterally and a mean 1.3±0.4 HPRO g/kg body weight in addition to SC. Nonresponsive patients received passive exercises and once responsive were encouraged to exercise actively. Primary outcome measures were muscle volume and cross-section area (CSA) measured using CT-imaging. Secondary outcomes included nutritional status, nitrogen balance, effect on delirium, and days on mechanical ventilation (MV).Results: On day 14, the NMES+HPRO+PT group lost significantly less muscle volume of both thighs and lower legs compared to SC group. The mean combined left and right thigh CSA and volume of the NMES+HPRO+PT group was significantly larger than the SC group on day 14. The nitrogen balance of the SC group was negative throughout the study duration, while the NMES+HPRO+PT group was positive on days 5, 9, and 14. At any time during their ICU stay SC patients experienced more delirium than the PT+NMES+HPRO group (46% vs 32%, p=0.09) although not statistically significant. There were no differences between groups when comparing length of stay or days on MV. Conclusion: The combination of NMES, HPRO and PT resulted in mitigation of lower extremity muscle loss and amelioration of clinical status of patients admitted to the ICU. The value of NMES, HPRO and PT independently in the initial and ongoing care of ICU survivors beyond 14 days of admission remains to be evaluated.Trial Registration: Clinicaltrials.gov identifier: NCT3195127